Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
Soy Carmín on MSN
11 Hollywood Stars We Have Sadly Lost to Cancer in the Last 5 Years
It’s always a gut punch when you hear that a face you’ve grown up with on screen is gone. These aren’t just celebrities; they’re the people who soundtracked our Friday nights and made us cry in ...
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussions OS ...
Stockhead on MSN
Health Check: Rhythm Biosciences is in the groove with first commercial sale of its bowel cancer assay
Rhythm Biosciences is entering a new commercial era, following the first sale of its revolutionary Colostat bowel cancer assay. ... Read More The post Health Check: Rhythm Biosciences is in the groove ...
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...
Leerink Global Healthcare Conference 2026 March 10, 2026 11:20 AM EDTCompany ParticipantsScott Reents - Executive VP & ...
Long viewed as a store of value, gold makes for a strategic asset in investment portfolios. According to the “Gold as a ...
Consumer Staples ended the day lower, while Tech once again emerged as the strongest sector (+1.9%). Within the Tech space, Life360 rallied 10.3% on news that it has now been added to the US S&P Small ...
Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
News-Medical.Net on MSN
FOXJ1 gene may drive resistance to taxane chemotherapy in advanced prostate cancer
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results